Chimerix (CMRX) PT Lowered to $14 at Wedbush, Following Recent Clinial Business Update
Tweet Send to a Friend
Wedbush analyst David Nierengarten lowered the price target on Chimerix (NASDAQ: CMRX) to $14.00 (from $15.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
